new semaglutide Popular weight-loss and diabetes medications show promise for curbing smoking, study suggests Novo Nordisk to launch Ozempic

We are excited to share that the Zepbound single-dose vials are now here, further delivering on our promise to increase supply of Zepbound in the U.S., Patrik Jonsson, Lilly executive vice president and president of Lilly Cardiometabolic Health and Lilly USA, said in the statement

Most patients tolerate GLP-1 medications well, and with appropriate management strategies, side effects can usually be minimised whilst maintaining the significant metabolic benefits these medications provide

Landmark trials showed robust weight loss with both semaglutide and tirzepatide

Insurance denials, lengthy approval processes, and restrictive criteria have left countless individuals without access to the most effective medical weight loss treatments available